Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study. Study treatment may not begin until a subject is registered. Inclusion Criteria: * Pathologic (histology or cytology) confirmed diagnosis of epithelial ovarian cancer or endometrial cancer * Radiographic evidence of recurrent epithelial ovarian cancer (ovarian, fallopian tube, or primary peritoneal cancer) or endometrial cancer that is "platinum-sensitive," defined as progression of disease beyond 6 months from the last dose of platinum-based chemotherapy * Female, age ≥ 18 years * World Health Organization (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks * Patient has measurable disease (at least one lesion that can be accurately assessed repeatedly by CT) as evidenced on pre-treatment baseline CT of Chest/Abdomen/Pelvis or PET/CT, or evaluable disease * Adequate hematologic counts, as defined below, without transfusion or growth factor support within 2 weeks of study drug initiation: * Hemoglobin ≥ 8.5 g/dL * Absolute neutrophil count ≥ 1500/mm3 * Platelets ≥ 100,000/μL * Adequate organ function as defined below: * Total bilirubin ≤ 1.5 ULN * AST(SGOT)/ALT(SPGT) ≤ 2.5x ULN or ≤ 5 x ULN if known liver metastases * Serum albumin \> 3 g/dL * Creatinine clearance ≥ 50 mL/min per the Cockcroft-Gault equation * Women of childbearing potential must agree to use adeq…